Drug Information

Drug General Information
Drug ID
D0BU5U
Former ID
DNC001143
Drug Name
PP2
Drug Type
Small molecular drug
Indication Discovery agent Investigative [535940]
Structure
Download
2D MOL

3D MOL
Formula
C15H16ClN5
Canonical SMILES
CC(C)(C)N1C2=C(C(=N1)C3=CC=C(C=C3)Cl)C(=NC=N2)N
InChI
1S/C15H16ClN5/c1-15(2,3)21-14-11(13(17)18-8-19-14)12(20-21)9-4-6-10(16)7-5-9/h4-8H,1-3H3,(H2,17,18,19)
InChIKey
PBBRWFOVCUAONR-UHFFFAOYSA-N
CAS Number
CAS 37321-09-8
PubChem Compound ID
4878
PubChem Substance ID
842091, 1824409, 3198210, 5015937, 7980429, 8152998, 11121744, 11122224, 11362872, 11365434, 11367996, 11370955, 11370956, 11373597, 11376158, 14720328, 14898464, 17402368, 25784347, 26756748, 26756749, 26759387, 26759389, 29223959, 46393019, 47216596, 47588812, 47588813, 47736276, 47736277, 47959550, 50111406, 53787734, 53800584, 56373967, 57322499, 57581298, 78228220, 85787287, 85789462, 89704588, 90945043, 92310095, 99222858, 99234352, 99301007, 99302527, 103102516, 103219431, 103904781
Target and Pathway
Target(s) Tyrosine-protein kinase 6 Target Info Inhibitor [535940]
WikiPathways EGF/EGFR Signaling Pathway
Focal Adhesion
References
Ref 535940Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.
Ref 535940Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.